Brio Capital

Brio Capital is a New York-based investment firm specializing in structured growth capital for micro-cap and small-cap companies within the life sciences and healthcare sectors. Founded in 2006 by Shaye Hirsch, the firm provides financing solutions such as Private Investment in Public Equity (PIPE) to clinical-stage biotechnology and medical technology companies. Brio Capital typically acts as a strategic financial partner, supporting portfolio companies as they advance through critical clinical trials and regulatory milestones. The firm's investment history spans a broad range of therapeutic focus areas, including oncology, infectious diseases, and advanced cardiovascular care. Notable portfolio investments include emerging biopharmaceutical developers such as BriaCell Therapeutics, Biodexa Pharmaceuticals, and Quoin Pharmaceuticals. Through its flagship Brio Capital Master Fund, the firm maintains a significant role in the funding ecosystem for early-stage and micro-cap healthcare innovators.